<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators</title>
  <meta name="description" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  <meta name="generator" content="bookdown 0.26 and GitBook 2.6.7" />

  <meta property="og:title" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  <meta property="og:type" content="book" />
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="2 The HIV/AIDS epidemic | Bayesian spatio-temporal methods for small-area estimation of HIV indicators" />
  
  
  

<meta name="author" content="Adam Howes" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="introduction.html"/>
<link rel="next" href="bayes-st.html"/>
<style type="text/css">
p.abstract{
  text-align: center;
  font-weight: bold;
}
div.abstract{
  margin: auto;
  width: 90%;
}
</style>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>


<style type="text/css">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {   }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { color: #008000; } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { color: #008000; font-weight: bold; } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */
</style>

<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="templates/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome</a>
<ul>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html#acknowledgments"><i class="fa fa-check"></i>Acknowledgments</a></li>
</ul></li>
<li class="chapter" data-level="1" data-path="introduction.html"><a href="introduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="introduction.html"><a href="introduction.html#chapter-overview"><i class="fa fa-check"></i><b>1.1</b> Chapter overview</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="hiv-aids.html"><a href="hiv-aids.html"><i class="fa fa-check"></i><b>2</b> The HIV/AIDS epidemic</a>
<ul>
<li class="chapter" data-level="2.1" data-path="hiv-aids.html"><a href="hiv-aids.html#background"><i class="fa fa-check"></i><b>2.1</b> Background</a></li>
<li class="chapter" data-level="2.2" data-path="hiv-aids.html"><a href="hiv-aids.html#surveillance"><i class="fa fa-check"></i><b>2.2</b> HIV surveillance</a>
<ul>
<li class="chapter" data-level="2.2.1" data-path="hiv-aids.html"><a href="hiv-aids.html#hiv-data"><i class="fa fa-check"></i><b>2.2.1</b> Data</a></li>
<li class="chapter" data-level="2.2.2" data-path="hiv-aids.html"><a href="hiv-aids.html#challenges"><i class="fa fa-check"></i><b>2.2.2</b> Challenges</a></li>
<li class="chapter" data-level="2.2.3" data-path="hiv-aids.html"><a href="hiv-aids.html#statistical-approaches"><i class="fa fa-check"></i><b>2.2.3</b> Statistical approaches</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="bayes-st.html"><a href="bayes-st.html"><i class="fa fa-check"></i><b>3</b> Bayesian spatio-temporal statistics</a>
<ul>
<li class="chapter" data-level="3.1" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-statistics"><i class="fa fa-check"></i><b>3.1</b> Bayesian statistics</a>
<ul>
<li class="chapter" data-level="3.1.1" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-modelling"><i class="fa fa-check"></i><b>3.1.1</b> Bayesian modelling</a></li>
<li class="chapter" data-level="3.1.2" data-path="bayes-st.html"><a href="bayes-st.html#bayesian-computation"><i class="fa fa-check"></i><b>3.1.2</b> Bayesian computation</a></li>
<li class="chapter" data-level="3.1.3" data-path="bayes-st.html"><a href="bayes-st.html#interplay-between-modelling-and-computation"><i class="fa fa-check"></i><b>3.1.3</b> Interplay between modelling and computation</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="bayes-st.html"><a href="bayes-st.html#st-statistics"><i class="fa fa-check"></i><b>3.2</b> Spatio-temporal statistics</a>
<ul>
<li class="chapter" data-level="3.2.1" data-path="bayes-st.html"><a href="bayes-st.html#properties-of-spatio-temporal-data"><i class="fa fa-check"></i><b>3.2.1</b> Properties of spatio-temporal data</a></li>
<li class="chapter" data-level="3.2.2" data-path="bayes-st.html"><a href="bayes-st.html#small-area-estimation"><i class="fa fa-check"></i><b>3.2.2</b> Small-area estimation</a></li>
</ul></li>
<li class="chapter" data-level="3.3" data-path="bayes-st.html"><a href="bayes-st.html#model-structure"><i class="fa fa-check"></i><b>3.3</b> Model structure</a>
<ul>
<li class="chapter" data-level="3.3.1" data-path="bayes-st.html"><a href="bayes-st.html#linear-model"><i class="fa fa-check"></i><b>3.3.1</b> Linear model</a></li>
<li class="chapter" data-level="3.3.2" data-path="bayes-st.html"><a href="bayes-st.html#generalised-linear-model"><i class="fa fa-check"></i><b>3.3.2</b> Generalised linear model</a></li>
<li class="chapter" data-level="3.3.3" data-path="bayes-st.html"><a href="bayes-st.html#generalised-linear-mixed-effects-model"><i class="fa fa-check"></i><b>3.3.3</b> Generalised linear mixed effects model</a></li>
<li class="chapter" data-level="3.3.4" data-path="bayes-st.html"><a href="bayes-st.html#lgm"><i class="fa fa-check"></i><b>3.3.4</b> Latent Gaussian model</a></li>
<li class="chapter" data-level="3.3.5" data-path="bayes-st.html"><a href="bayes-st.html#elgm"><i class="fa fa-check"></i><b>3.3.5</b> Extended latent Gaussian model</a></li>
</ul></li>
<li class="chapter" data-level="3.4" data-path="bayes-st.html"><a href="bayes-st.html#model-comparison"><i class="fa fa-check"></i><b>3.4</b> Model comparison</a>
<ul>
<li class="chapter" data-level="3.4.1" data-path="bayes-st.html"><a href="bayes-st.html#information-criteria"><i class="fa fa-check"></i><b>3.4.1</b> Information criteria</a></li>
<li class="chapter" data-level="3.4.2" data-path="bayes-st.html"><a href="bayes-st.html#scoring-rules"><i class="fa fa-check"></i><b>3.4.2</b> Scoring rules</a></li>
</ul></li>
<li class="chapter" data-level="3.5" data-path="bayes-st.html"><a href="bayes-st.html#survey"><i class="fa fa-check"></i><b>3.5</b> Survey methods</a>
<ul>
<li class="chapter" data-level="3.5.1" data-path="bayes-st.html"><a href="bayes-st.html#survey-notation-and-key-terms"><i class="fa fa-check"></i><b>3.5.1</b> Survey notation and key terms</a></li>
<li class="chapter" data-level="3.5.2" data-path="bayes-st.html"><a href="bayes-st.html#survey-design"><i class="fa fa-check"></i><b>3.5.2</b> Survey design</a></li>
<li class="chapter" data-level="3.5.3" data-path="bayes-st.html"><a href="bayes-st.html#survey-analysis"><i class="fa fa-check"></i><b>3.5.3</b> Survey analysis</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="beyond-borders.html"><a href="beyond-borders.html"><i class="fa fa-check"></i><b>4</b> Models for spatial structure</a>
<ul>
<li class="chapter" data-level="4.1" data-path="beyond-borders.html"><a href="beyond-borders.html#adjacency-models"><i class="fa fa-check"></i><b>4.1</b> Models based on adjacency</a>
<ul>
<li class="chapter" data-level="4.1.1" data-path="beyond-borders.html"><a href="beyond-borders.html#besag"><i class="fa fa-check"></i><b>4.1.1</b> The Besag model</a></li>
<li class="chapter" data-level="4.1.2" data-path="beyond-borders.html"><a href="beyond-borders.html#best-practises-for-the-besag-model"><i class="fa fa-check"></i><b>4.1.2</b> Best practises for the Besag model</a></li>
<li class="chapter" data-level="4.1.3" data-path="beyond-borders.html"><a href="beyond-borders.html#concerns"><i class="fa fa-check"></i><b>4.1.3</b> Concerns about the Besag model</a></li>
<li class="chapter" data-level="4.1.4" data-path="beyond-borders.html"><a href="beyond-borders.html#weighted-icar-models"><i class="fa fa-check"></i><b>4.1.4</b> Weighted ICAR models</a></li>
<li class="chapter" data-level="4.1.5" data-path="beyond-borders.html"><a href="beyond-borders.html#bym2"><i class="fa fa-check"></i><b>4.1.5</b> The reparameterised Besag-York-Mollié model</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="beyond-borders.html"><a href="beyond-borders.html#kernel-models"><i class="fa fa-check"></i><b>4.2</b> Models using kernels</a>
<ul>
<li class="chapter" data-level="4.2.1" data-path="beyond-borders.html"><a href="beyond-borders.html#centroid-kernel"><i class="fa fa-check"></i><b>4.2.1</b> Centroid kernel</a></li>
<li class="chapter" data-level="4.2.2" data-path="beyond-borders.html"><a href="beyond-borders.html#integrated-kernel"><i class="fa fa-check"></i><b>4.2.2</b> Integrated kernel</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="beyond-borders.html"><a href="beyond-borders.html#simulation-study"><i class="fa fa-check"></i><b>4.3</b> Simulation study</a>
<ul>
<li class="chapter" data-level="4.3.1" data-path="beyond-borders.html"><a href="beyond-borders.html#synthetic-data"><i class="fa fa-check"></i><b>4.3.1</b> Synthetic data</a></li>
<li class="chapter" data-level="4.3.2" data-path="beyond-borders.html"><a href="beyond-borders.html#inferential-models"><i class="fa fa-check"></i><b>4.3.2</b> Inferential models</a></li>
<li class="chapter" data-level="4.3.3" data-path="beyond-borders.html"><a href="beyond-borders.html#model-assessment"><i class="fa fa-check"></i><b>4.3.3</b> Model assessment</a></li>
<li class="chapter" data-level="4.3.4" data-path="beyond-borders.html"><a href="beyond-borders.html#results"><i class="fa fa-check"></i><b>4.3.4</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="beyond-borders.html"><a href="beyond-borders.html#hiv-study"><i class="fa fa-check"></i><b>4.4</b> HIV prevalence study</a>
<ul>
<li class="chapter" data-level="4.4.1" data-path="beyond-borders.html"><a href="beyond-borders.html#household-survey-data"><i class="fa fa-check"></i><b>4.4.1</b> Household survey data</a></li>
<li class="chapter" data-level="4.4.2" data-path="beyond-borders.html"><a href="beyond-borders.html#inferential-models-1"><i class="fa fa-check"></i><b>4.4.2</b> Inferential models</a></li>
<li class="chapter" data-level="4.4.3" data-path="beyond-borders.html"><a href="beyond-borders.html#model-comparison-1"><i class="fa fa-check"></i><b>4.4.3</b> Model comparison</a></li>
<li class="chapter" data-level="4.4.4" data-path="beyond-borders.html"><a href="beyond-borders.html#results-1"><i class="fa fa-check"></i><b>4.4.4</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="4.5" data-path="beyond-borders.html"><a href="beyond-borders.html#discussion"><i class="fa fa-check"></i><b>4.5</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="multi-agyw.html"><a href="multi-agyw.html"><i class="fa fa-check"></i><b>5</b> A model for risk group proportions</a>
<ul>
<li class="chapter" data-level="5.1" data-path="multi-agyw.html"><a href="multi-agyw.html#background-1"><i class="fa fa-check"></i><b>5.1</b> Background</a></li>
<li class="chapter" data-level="5.2" data-path="multi-agyw.html"><a href="multi-agyw.html#data"><i class="fa fa-check"></i><b>5.2</b> Data</a>
<ul>
<li class="chapter" data-level="5.2.1" data-path="multi-agyw.html"><a href="multi-agyw.html#behavioural-data-from-household-surveys"><i class="fa fa-check"></i><b>5.2.1</b> Behavioural data from household surveys</a></li>
<li class="chapter" data-level="5.2.2" data-path="multi-agyw.html"><a href="multi-agyw.html#other-data"><i class="fa fa-check"></i><b>5.2.2</b> Other data</a></li>
</ul></li>
<li class="chapter" data-level="5.3" data-path="multi-agyw.html"><a href="multi-agyw.html#model-for-risk-group-proportions"><i class="fa fa-check"></i><b>5.3</b> Model for risk group proportions</a>
<ul>
<li class="chapter" data-level="5.3.1" data-path="multi-agyw.html"><a href="multi-agyw.html#st-multinomial"><i class="fa fa-check"></i><b>5.3.1</b> Spatio-temporal multinomial logistic regression</a></li>
<li class="chapter" data-level="5.3.2" data-path="multi-agyw.html"><a href="multi-agyw.html#s-logistic"><i class="fa fa-check"></i><b>5.3.2</b> Spatial logistic regression</a></li>
<li class="chapter" data-level="5.3.3" data-path="multi-agyw.html"><a href="multi-agyw.html#model-combination"><i class="fa fa-check"></i><b>5.3.3</b> Model combination</a></li>
<li class="chapter" data-level="5.3.4" data-path="multi-agyw.html"><a href="multi-agyw.html#female-sex-worker-population-size-adjustment"><i class="fa fa-check"></i><b>5.3.4</b> Female sex worker population size adjustment</a></li>
<li class="chapter" data-level="5.3.5" data-path="multi-agyw.html"><a href="multi-agyw.html#results-2"><i class="fa fa-check"></i><b>5.3.5</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="5.4" data-path="multi-agyw.html"><a href="multi-agyw.html#prevalence-and-incidence-by-risk-group"><i class="fa fa-check"></i><b>5.4</b> Prevalence and incidence by risk group</a>
<ul>
<li class="chapter" data-level="5.4.1" data-path="multi-agyw.html"><a href="multi-agyw.html#disaggregation-of-naomi-prevalence-estimates"><i class="fa fa-check"></i><b>5.4.1</b> Disaggregation of Naomi prevalence estimates</a></li>
<li class="chapter" data-level="5.4.2" data-path="multi-agyw.html"><a href="multi-agyw.html#disaggregation-of-naomi-incidence-estimates"><i class="fa fa-check"></i><b>5.4.2</b> Disaggregation of Naomi incidence estimates</a></li>
<li class="chapter" data-level="5.4.3" data-path="multi-agyw.html"><a href="multi-agyw.html#expected-new-infections-reached"><i class="fa fa-check"></i><b>5.4.3</b> Expected new infections reached</a></li>
<li class="chapter" data-level="5.4.4" data-path="multi-agyw.html"><a href="multi-agyw.html#results-3"><i class="fa fa-check"></i><b>5.4.4</b> Results</a></li>
</ul></li>
<li class="chapter" data-level="5.5" data-path="multi-agyw.html"><a href="multi-agyw.html#discussion-1"><i class="fa fa-check"></i><b>5.5</b> Discussion</a>
<ul>
<li class="chapter" data-level="5.5.1" data-path="multi-agyw.html"><a href="multi-agyw.html#limitations"><i class="fa fa-check"></i><b>5.5.1</b> Limitations</a></li>
<li class="chapter" data-level="5.5.2" data-path="multi-agyw.html"><a href="multi-agyw.html#conclusion"><i class="fa fa-check"></i><b>5.5.2</b> Conclusion</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="naomi-aghq.html"><a href="naomi-aghq.html"><i class="fa fa-check"></i><b>6</b> Fast approximate Bayesian inference</a>
<ul>
<li class="chapter" data-level="6.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-inference"><i class="fa fa-check"></i><b>6.1</b> Inference methods and software</a>
<ul>
<li class="chapter" data-level="6.1.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#la"><i class="fa fa-check"></i><b>6.1.1</b> The Laplace approximation</a></li>
<li class="chapter" data-level="6.1.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#quadrature"><i class="fa fa-check"></i><b>6.1.2</b> Quadrature</a></li>
<li class="chapter" data-level="6.1.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#inla"><i class="fa fa-check"></i><b>6.1.3</b> Integrated nested Laplace approximation</a></li>
<li class="chapter" data-level="6.1.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#software"><i class="fa fa-check"></i><b>6.1.4</b> Software</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#universal"><i class="fa fa-check"></i><b>6.2</b> A universal INLA implementation</a>
<ul>
<li class="chapter" data-level="6.2.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#epil"><i class="fa fa-check"></i><b>6.2.1</b> Epilepsy GLMM</a></li>
<li class="chapter" data-level="6.2.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#loaloa"><i class="fa fa-check"></i><b>6.2.2</b> Loa loa ELGM</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi"><i class="fa fa-check"></i><b>6.3</b> The Naomi model</a>
<ul>
<li class="chapter" data-level="6.3.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-model"><i class="fa fa-check"></i><b>6.3.1</b> Model structure</a></li>
<li class="chapter" data-level="6.3.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#naomi-elgm"><i class="fa fa-check"></i><b>6.3.2</b> Naomi as an ELGM</a></li>
</ul></li>
<li class="chapter" data-level="6.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#pca-aghq"><i class="fa fa-check"></i><b>6.4</b> AGHQ in moderate dimensions</a>
<ul>
<li class="chapter" data-level="6.4.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#aghq-with-variable-levels"><i class="fa fa-check"></i><b>6.4.1</b> AGHQ with variable levels</a></li>
<li class="chapter" data-level="6.4.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#principal-components-analysis"><i class="fa fa-check"></i><b>6.4.2</b> Principal components analysis</a></li>
</ul></li>
<li class="chapter" data-level="6.5" data-path="naomi-aghq.html"><a href="naomi-aghq.html#malawi"><i class="fa fa-check"></i><b>6.5</b> Malawi case-study</a>
<ul>
<li class="chapter" data-level="6.5.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#nuts-convergence"><i class="fa fa-check"></i><b>6.5.1</b> NUTS convergence</a></li>
<li class="chapter" data-level="6.5.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#use-of-pca-aghq"><i class="fa fa-check"></i><b>6.5.2</b> Use of PCA-AGHQ</a></li>
<li class="chapter" data-level="6.5.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#model-assessment-1"><i class="fa fa-check"></i><b>6.5.3</b> Model assessment</a></li>
<li class="chapter" data-level="6.5.4" data-path="naomi-aghq.html"><a href="naomi-aghq.html#inference-comparison"><i class="fa fa-check"></i><b>6.5.4</b> Inference comparison</a></li>
<li class="chapter" data-level="6.5.5" data-path="naomi-aghq.html"><a href="naomi-aghq.html#exceedance-probabilities"><i class="fa fa-check"></i><b>6.5.5</b> Exceedance probabilities</a></li>
</ul></li>
<li class="chapter" data-level="6.6" data-path="naomi-aghq.html"><a href="naomi-aghq.html#discussion-2"><i class="fa fa-check"></i><b>6.6</b> Discussion</a>
<ul>
<li class="chapter" data-level="6.6.1" data-path="naomi-aghq.html"><a href="naomi-aghq.html#a-universal-inla-implementation"><i class="fa fa-check"></i><b>6.6.1</b> A universal INLA implementation</a></li>
<li class="chapter" data-level="6.6.2" data-path="naomi-aghq.html"><a href="naomi-aghq.html#pca-aghq-with-application-to-inla-for-naomi"><i class="fa fa-check"></i><b>6.6.2</b> PCA-AGHQ with application to INLA for Naomi</a></li>
<li class="chapter" data-level="6.6.3" data-path="naomi-aghq.html"><a href="naomi-aghq.html#suggestions-for-future-work"><i class="fa fa-check"></i><b>6.6.3</b> Suggestions for future work</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="7" data-path="conclusions.html"><a href="conclusions.html"><i class="fa fa-check"></i><b>7</b> Conclusions</a>
<ul>
<li class="chapter" data-level="7.1" data-path="conclusions.html"><a href="conclusions.html#strengths"><i class="fa fa-check"></i><b>7.1</b> Strengths</a></li>
<li class="chapter" data-level="7.2" data-path="conclusions.html"><a href="conclusions.html#weaknesses"><i class="fa fa-check"></i><b>7.2</b> Weaknesses</a></li>
<li class="chapter" data-level="7.3" data-path="conclusions.html"><a href="conclusions.html#future-work"><i class="fa fa-check"></i><b>7.3</b> Future work</a></li>
<li class="chapter" data-level="7.4" data-path="conclusions.html"><a href="conclusions.html#conclusions-1"><i class="fa fa-check"></i><b>7.4</b> Conclusions</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="models-for-spatial-structure.html"><a href="models-for-spatial-structure.html"><i class="fa fa-check"></i><b>A</b> Models for spatial structure</a>
<ul>
<li class="chapter" data-level="A.1" data-path="models-for-spatial-structure.html"><a href="models-for-spatial-structure.html#aghq-nuts"><i class="fa fa-check"></i><b>A.1</b> Comparison of AGHQ to NUTS</a></li>
<li class="chapter" data-level="A.2" data-path="models-for-spatial-structure.html"><a href="models-for-spatial-structure.html#simulation-study-1"><i class="fa fa-check"></i><b>A.2</b> Simulation study</a></li>
<li class="chapter" data-level="A.3" data-path="models-for-spatial-structure.html"><a href="models-for-spatial-structure.html#hiv-study-1"><i class="fa fa-check"></i><b>A.3</b> HIV study</a></li>
</ul></li>
<li class="chapter" data-level="B" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html"><i class="fa fa-check"></i><b>B</b> A model for risk group proportions</a>
<ul>
<li class="chapter" data-level="B.1" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#the-global-aids-strategy"><i class="fa fa-check"></i><b>B.1</b> The Global AIDS Strategy</a></li>
<li class="chapter" data-level="B.2" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#household-survey-data-1"><i class="fa fa-check"></i><b>B.2</b> Household survey data</a></li>
<li class="chapter" data-level="B.3" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#spatial-analysis-levels"><i class="fa fa-check"></i><b>B.3</b> Spatial analysis levels</a></li>
<li class="chapter" data-level="B.4" data-path="a-model-for-risk-group-proportions.html"><a href="a-model-for-risk-group-proportions.html#survey-questions"><i class="fa fa-check"></i><b>B.4</b> Survey questions and risk group allocation</a></li>
</ul></li>
<li class="chapter" data-level="C" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html"><i class="fa fa-check"></i><b>C</b> Fast approximate Bayesian inference</a>
<ul>
<li class="chapter" data-level="C.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#epilepsy-example"><i class="fa fa-check"></i><b>C.1</b> Epilepsy example</a>
<ul>
<li class="chapter" data-level="C.1.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#tmb-epil"><i class="fa fa-check"></i><b>C.1.1</b> <code>TMB</code> C++ template</a></li>
<li class="chapter" data-level="C.1.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#tmb-modified-epil"><i class="fa fa-check"></i><b>C.1.2</b> Modified <code>TMB</code> C++ template</a></li>
<li class="chapter" data-level="C.1.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#stan-epil"><i class="fa fa-check"></i><b>C.1.3</b> <code>Stan</code> C++ template</a></li>
<li class="chapter" data-level="C.1.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#nuts-convergence-diagnostics"><i class="fa fa-check"></i><b>C.1.4</b> NUTS convergence diagnostics</a></li>
</ul></li>
<li class="chapter" data-level="C.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-math"><i class="fa fa-check"></i><b>C.2</b> Simplified Naomi model description</a>
<ul>
<li class="chapter" data-level="C.2.1" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-process"><i class="fa fa-check"></i><b>C.2.1</b> Process specification</a></li>
<li class="chapter" data-level="C.2.2" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-likelihood"><i class="fa fa-check"></i><b>C.2.2</b> Additional likelihood specification</a></li>
<li class="chapter" data-level="C.2.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-identifiability"><i class="fa fa-check"></i><b>C.2.3</b> Identifiability constraints</a></li>
<li class="chapter" data-level="C.2.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#naomi-implementation"><i class="fa fa-check"></i><b>C.2.4</b> Implementation</a></li>
</ul></li>
<li class="chapter" data-level="C.3" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#model-assessment-2"><i class="fa fa-check"></i><b>C.3</b> Model assessment</a></li>
<li class="chapter" data-level="C.4" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#aghq-and-pca-aghq-details"><i class="fa fa-check"></i><b>C.4</b> AGHQ and PCA-AGHQ details</a></li>
<li class="chapter" data-level="C.5" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#normalising-constant-estimation"><i class="fa fa-check"></i><b>C.5</b> Normalising constant estimation</a></li>
<li class="chapter" data-level="C.6" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#inference-comparison-1"><i class="fa fa-check"></i><b>C.6</b> Inference comparison</a></li>
<li class="chapter" data-level="C.7" data-path="fast-approximate-bayesian-inference.html"><a href="fast-approximate-bayesian-inference.html#mcmc-convergence-and-suitability"><i class="fa fa-check"></i><b>C.7</b> MCMC convergence and suitability</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"><p>Bayesian spatio-temporal methods for small-area estimation of HIV indicators</p></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="hiv-aids" class="section level1 hasAnchor" number="2">
<h1><span class="header-section-number">2</span> The HIV/AIDS epidemic<a href="hiv-aids.html#hiv-aids" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<!-- For PDF output, include these two LaTeX commands after unnumbered chapter headings, otherwise the mini table of contents and the running header will show the previous chapter -->
<div id="background" class="section level2 hasAnchor" number="2.1">
<h2><span class="header-section-number">2.1</span> Background<a href="hiv-aids.html#background" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<!-- What is HIV -->
<p>HIV is a retrovirus which infects humans.
If untreated, HIV can develop into a more advanced stage known as acquired immunodeficiency syndrome (AIDS).
HIV primarily attacks a type of white blood cell vital for the function of the immune system.
As a result, AIDS is characterised by increased risk of developing opportunistic infections such as tuberculosis or <em>Pneumocystis</em> pneumonias, which can result in death.</p>
<!-- HIV is a big problem, plus how is it transmitted -->
<p>The first AIDS cases were reported in Los Angeles in the early 1980s <span class="citation">(<a href="#ref-gottlieb1981pneumocystis">Gottlieb et al. 1981</a>; <a href="#ref-barre1983isolation">Barré-Sinoussi et al. 1983</a>)</span>.
Since then, HIV has spread globally.
Transmission occurs by exposure to specific bodily fluids of an infected person.
The most common mode of transmission is via unprotected anal or vaginal sex, though transmission can also occur from a mother to her baby, or when drug injection equipment is shared.
Approximately 86 million people have become infected with HIV, and of those 40 million have died of AIDS-related causes.</p>
<!-- A lot of effort going into it -->
<p>An ongoing global and multifaceted effort has been made to respond to the epidemic.
The response has been shaped by local communities, civil society organisations, national governments, research institutions, pharmaceutical companies, international agencies like the Joint United Nations Programme
on HIV/AIDS (UNAIDS), and global health initiatives such like the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund).
To give an indication as to the scale of the response, the investment of $100 billion by PEPFAR constitutes the “largest commitment by a single nation to address a single disease in history” <span class="citation">(<a href="#ref-pepfar2022">U.S. Department of State 2022</a>)</span>.</p>

<div class="figure" style="text-align: centre"><span style="display:block;" id="fig:overall-picture"></span>
<img src="figures/hiv-aids/overall-picture.png" alt="Globally, yearly new HIV infections peaked in 1995, and have since decreased by 59% and yearly AIDS-related deaths peaked in 2004, and have since decreased by 68% (UNAIDS 2023a). Much of the disease burden is concentrated in eastern and southern Africa, as well as western and central Africa." width="95%" />
<p class="caption">
Figure 2.1: Globally, yearly new HIV infections peaked in 1995, and have since decreased by 59% and yearly AIDS-related deaths peaked in 2004, and have since decreased by 68% <span class="citation">(<a href="#ref-unaids2023aidsinfo">UNAIDS 2023a</a>)</span>. Much of the disease burden is concentrated in eastern and southern Africa, as well as western and central Africa.
</p>
</div>
<!-- The effort has translated into progress -->
<p>Implementation of HIV prevention and treatment has significantly reduced the number of new HIV infections and AIDS-related deaths per year since their peak (Figure <a href="hiv-aids.html#fig:overall-picture">2.1</a>).
The most significant evidence-based interventions, in chronological order of their introduction, are described below:</p>
<ul>
<li><p>Condoms are an inexpensive and effective method for prevention of HIV and other sexually transmitted infections (STIs) such as <em>Chlamydia trachomatis</em>, <em>Neisseria gonorrhoeae</em>, syphilis, and <em>Trichomonas vaginalis</em>.
Condom usage has increased significantly since 1990, which is estimated to have averted 117 million new HIV infections <span class="citation">(<a href="#ref-stover2021impact">Stover and Teng 2021</a>)</span>.
There remain significant but difficult to close gaps in condom usage.</p></li>
<li><p>Antiretroviral therapy (ART) is a combination of drugs which stop the virus from replicating in the body.
A person living with HIV who takes ART daily can live a full and healthy life, transforming what was once a terminal illness to a treatable chronic condition.
Of the 39 million people living with HIV (PLHIV) in 2022, around 76% were accessing ART.
The number of AIDS-related deaths, 21 million, estimated to have been averted by ART is staggering <span class="citation">(<a href="#ref-unaids2023global">UNAIDS 2023b</a>)</span>.</p>
<p>ART reduces the amount of virus in the blood and genital secretions.
If the virus is undetectable then there is significant evidence that it cannot be transmitted sexually <span class="citation">(<a href="#ref-cohen2011prevention">Cohen et al. 2011</a>; <a href="#ref-broyles2023risk">Broyles et al. 2023</a>)</span>.
For this reason, in addition to providing life saving treatment, ART also operates as prevention.
Approaches to lowering risk of HIV transmission using treatment are referred to as treatment as prevention (TaSP).
Particular efforts have been made to provide pregnant women with ART to reduce the chance of mother-to-child transmission (MTCT) <span class="citation">(<a href="#ref-siegfried2011antiretrovirals">Siegfried et al. 2011</a>)</span>.</p></li>
<li><p>Voluntary medical male circumcision (VMMC) partially protects against female-to-male HIV acquisition.
Three landmark randomised control trials <span class="citation">(<a href="#ref-auvert2005randomized">Auvert et al. 2005</a>; <a href="#ref-gray2007male">Gray et al. 2007</a>; <a href="#ref-bailey2007male">Bailey et al. 2007</a>)</span> found complete surgical removal of the foreskin to result a reduction of HIV acquisition in men by 50-60%.
Based on this evidence, VMMC has been recommended since 2007 by the World Health Organization (WHO) and UNAIDS as a key HIV intervention in high-prevalence settings.
Scale up of VMMC across 15 priority countries between 2008 and 2019 is estimated to have already averted 340 thousand new HIV infections, though the future number of new HIV infections averted is likely to be much higher.</p></li>
<li><p>Pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) are antiretrovial drugs which can be taken before and after exposure to prevent transmission.
PrEP and PEP are more costly than some other prevention options, so primarily useful in high risk settings.</p></li>
</ul>
<p>Though important progress had been made, facilitated by the interventions above, there remains much more to do.
In 2022, 1.3 million people were newly infected with HIV and there were 630 thousand AIDS-related deaths, more than one every minute <span class="citation">(<a href="#ref-unaids2022global">UNAIDS 2022</a>)</span>.
Bold fast-track targets have been set to accelerate the end of AIDS as global public health threat by 2030.
To meet these targets in the context of disruption to HIV services caused by the COVID-19 pandemic and a potential shortfall in HIV funding, renewed commitments are required <span class="citation">(<a href="#ref-economist2023triple">Economist Impact 2023</a>)</span>.</p>

<div class="figure" style="text-align: centre"><span style="display:block;" id="fig:naomi-continent"></span>
<img src="figures/hiv-aids/naomi-continent.png" alt="Adult (15-49) HIV prevalence varies substantially both within and between countries in SSA. The estimates from 2023 were generated by country teams using the Naomi small-area estimation model in a process supported by UNAIDS, and are available from UNAIDS (2023a). White filled points are country-level estimates, and coloured points are district-level estimates. Results from Nigeria were not published. Data collection in the Cabo Delgado province of Mozambique was disrupted by conflict. Obtaining results for the Democratic Republic of the Congo required removing some districts from the model." width="95%" />
<p class="caption">
Figure 2.2: Adult (15-49) HIV prevalence varies substantially both within and between countries in SSA. The estimates from 2023 were generated by country teams using the Naomi small-area estimation model in a process supported by UNAIDS, and are available from <span class="citation">UNAIDS (<a href="#ref-unaids2023aidsinfo">2023a</a>)</span>. White filled points are country-level estimates, and coloured points are district-level estimates. Results from Nigeria were not published. Data collection in the Cabo Delgado province of Mozambique was disrupted by conflict. Obtaining results for the Democratic Republic of the Congo required removing some districts from the model.
</p>
</div>
<!-- Prioritisation of interventions  -->
<p>For available resources to have the greatest impact, it is important that the right HIV interventions to be prioritised to the right populations, in the right place, and at the right time.
This paradigm has been termed precision public health <span class="citation">(<a href="#ref-khoury2016precision">Khoury, Iademarco, and Riley 2016</a>)</span>, by analogy to precision medicine.
While precision medicine tailors treatment to the individual, precision public health tailors treatment to the population.
Differences in the cost-effectiveness of any given intervention can be vast, with some interventions orders of magnitude more impactful than others <span class="citation">(<a href="#ref-ord2013moral">Ord 2013</a>)</span>.</p>
<!-- Uneven burden in space -->
<p>Disease burden varies substantially across multiple spatial scales.
In some countries, the epidemic is concentrated in small populations, and national HIV prevalence is low.
In others, the epidemic is sustained by heterosexual transmission, and national HIV prevalence is higher (typically &gt;1%)
These two epidemic settings are sometimes described as concentrated and generalised, respectively.
Most of the countries severely affected by HIV are in sub-Saharan Africa (SSA).
It is estimated that 66% of the 39 million PLHIV worldwide live in SSA.
Adult HIV prevalence (ages 15-49) is above than 10% (Figure <a href="hiv-aids.html#fig:naomi-continent">2.2</a>) in some countries in southern Africa, with some districts even exceeding 20%.
Just as there is variation between countries, there is variation within countries.
For example, adult HIV prevalence at the district municipality level in South Africa ranges from 6% in Namakwa to 30% in uMkhanyakude.</p>
<!-- Uneven burden across people -->
<p>In all countries and contexts, some groups of people are at much higher risk than others.
Groups of people at increased risk of HIV infection are known as key populations (KPs).
Examples include men who have sex with men (MSM), female sex workers (FSW), people who inject drugs (PWID), and transgender people (TGP) <span class="citation">(<a href="#ref-stevens2022key">Stevens, Sabin, Garcia, et al. 2022</a>)</span>.
KPs are often marginalised, and face legal and social barriers.
Concentrated settings are defined by the majority of new HIV infections occurring in KPs and their sexual partners.
In generalised settings like SSA, risk is more diffuse across the population.
For example, in SSA adolescent girls and young women (AGYW) are a large demographic group at increased risk of HIV infection <span class="citation">(<a href="#ref-risher2021age">Risher et al. 2021</a>; <a href="#ref-monod2023growing">Monod et al. 2023</a>)</span> but not typically considered a KP.
That said, concentrated subepidemics often occur within what are nominally generalised settings <span class="citation">(<a href="#ref-tanser2014concentrated">Tanser et al. 2014</a>)</span>.</p>
<!-- Practical methods for prevention prioritisation: what is being done and is it working -->
<p>Differentiated HIV treatment and prevention services can be practically implemented via a number of approaches <span class="citation">(<a href="#ref-eaton2022aids">W. J. Eaton 2022</a>)</span>.
These include geographic and demographic prioritisation, key and vulnerable population services, and risk screening based on individual-level risk characteristics.</p>
</div>
<div id="surveillance" class="section level2 hasAnchor" number="2.2">
<h2><span class="header-section-number">2.2</span> HIV surveillance<a href="hiv-aids.html#surveillance" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<!-- What is surveillance and how can it be used to meet these needs -->
<p>HIV surveillance refers to the collection, analysis, interpretation and dissemination of data relating to HIV <span class="citation">(<a href="#ref-pisani2003hiv">Pisani et al. 2003</a>)</span>.
Surveillance can used to track epidemic indicators, identify at-risk populations, find drivers of transmission, and evaluate the impact of prevention and treatment programs.
Important indicators include:</p>
<ul>
<li><p><strong>HIV prevalence</strong> is the proportion <span class="math inline">\(\rho \in [0, 1]\)</span> of a population who have HIV.
The number of PLHIV is given by <span class="math inline">\(N\rho\)</span>, where <span class="math inline">\(N\)</span> is the (living) population size.
Increases in HIV prevalence, or the number of PLHIV, can be caused by either new HIV infections or more PLHIV remaining alive by taking treatment.
For this reason care must be taken in directly interpreting changes in HIV prevalence.
As a key measure of population disease burden, HIV prevalence is used to calculate all of the other indicators given below.</p></li>
<li><p><strong>HIV incidence</strong> is the rate <span class="math inline">\(\lambda &gt; 0\)</span> of new HIV infections, often written as number of new infections per 1000 person years.
The number of new HIV infections that occur during a given time is the integral of HIV incidence multiplied by the size of the susceptible population.
Let <span class="math inline">\(\rho_t\)</span> be the HIV prevalence, and <span class="math inline">\(N_t\)</span> be the population size, at time <span class="math inline">\(t\)</span>.
Then the number of new HIV infections which occur in a given period of time are given by
<span class="math display">\[
I = \int \lambda_t \cdot (1 - \rho_t) \cdot N_t \text{d}t.
\]</span>
Planning, delivery, and evaluation of prevention programming relies on estimates of HIV incidence and the number of new HIV infections.</p></li>
<li><p><strong>ART coverage</strong> is the proportion <span class="math inline">\(\alpha \in [0, 1]\)</span> of PLHIV who are on ART.
Estimates of ART coverage play a direct role in planning the provision of treatment services.
The number of people taking ART is given by <span class="math inline">\(N \cdot \rho \cdot \alpha\)</span>.</p></li>
<li><p><strong>Recent infection</strong> is the proportion <span class="math inline">\(\kappa \in [0, 1]\)</span> of PLHIV who have been recently infected.
Recent infection can be used to help estimate HIV incidence.</p></li>
<li><p><strong>Awareness of status</strong> is the proportion <span class="math inline">\(\xi \in [0, 1]\)</span> of PLHIV who have been diagnosed with HIV.
Programming of HIV testing and diagnosis is informed by awareness of status.</p></li>
</ul>
<div id="hiv-data" class="section level3 hasAnchor" number="2.2.1">
<h3><span class="header-section-number">2.2.1</span> Data<a href="hiv-aids.html#hiv-data" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Data are used to estimate the above HIV indicators, in conjunction with scientific knowledge.
Multiple sources of data are used:</p>
<ul>
<li><p><strong>Household surveys</strong> are large, national cross-sectional studies.
The Demographic and Health Surveys (DHS) Program.
Population-based HIV Impact Assessments (PHIA).
Household surveys provide nationally-representative high quality standardised data about HIV.</p></li>
<li><p><strong>Programmatic data</strong> refer to data routinely collected during delivery of health services.
Examples include data from antenatal care (ANC) HIV testing and ART service delivery.
Programmatic data are more regularly available than other data sources.
However, the control that can be exercised over collection of programmatic data is limited.
As a result, issues of data quality and reliability, as well as bias, are common in working with programmatic data.</p></li>
<li><p><strong>Cohort studies</strong> follow a group of people over time.
Outcomes may be measured more systematically in a cohort study than in other study designs.
The data from cohort studies are used to inform otherwise difficult to estimate epidemiological parameters.
Examples of such parameters include disease progression and mortality rates, transmission dynamics, and treatment outcomes.
Population-based cohort studies relevant to the SSA setting include Manicaland, Zimbabwe <span class="citation">(<a href="#ref-gregson2006hiv">Gregson et al. 2006</a>)</span>; Rakai, Uganda <span class="citation">(<a href="#ref-grabowski2017hiv">Grabowski et al. 2017</a>)</span>.</p></li>
</ul>
<!-- Discuss methods for HIV testing -->
</div>
<div id="challenges" class="section level3 hasAnchor" number="2.2.2">
<h3><span class="header-section-number">2.2.2</span> Challenges<a href="hiv-aids.html#challenges" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Obtaining reliable, timely estimates at an appropriate spatial resolution is challenging.
The most significant difficulties faced are:</p>
<ol style="list-style-type: decimal">
<li><p><strong>Data sparsity</strong>:
Collection of data is costly and time consuming.
As a result, limited direct data might be available for the particular time, location, or population of interest.
For example, in many countries the last conducted household survey is several years out of date.</p></li>
<li><p><strong>Missing data</strong>:
The sampling frame of a survey may not correspond to the target population.
For example, many KPs are difficult to reach, and may be omitted from sampling frames.
Individuals included on the sampling frame may choose not to respond.
All surveys are subject to sampling error, as only a subset of the target population are sampled.
Each of these issues can be characterised as being problems of missing data.
I characterise missing data as referring to the shortfalls of any given study, and data sparsity as referring to limited availability of studies.</p></li>
<li><p><strong>Response and measurement biases</strong>:
Individuals may be hesitant to disclose their HIV status, or report higher risk behaviours, due to social desirability bias or a fear of discrimination or stigma.
When available, biomarker data can be used to overcome under-reporting, but still may be subject to measurement errors.</p></li>
<li><p><strong>Denominators and demography</strong>:
Many indicators are rates or proportions, which rely on estimates of the population at risk in the denominator.
Accurately estimating population denominators is itself a challenging task <span class="citation">(<a href="#ref-tatem2017worldpop">Tatem 2017</a>)</span>.
Taking a ratio of uncertain quantities amplifies uncertainty, but is rarely properly accounted for.</p></li>
<li><p><strong>Inconsistent data collection and reporting</strong>:
The types of data that are collected might vary across space and time.
Reporting protocols or definitions can also change.</p></li>
<li><p><strong>Reliance on epidemiological parameters</strong>:
Indicators rely on estimates of epidemiological parameters such as rates of disease progression.
These parameters may not generalise to the setting of interest.
Further, they are typically applied coarsely, and without proper accounting for uncertainty.</p></li>
</ol>
</div>
<div id="statistical-approaches" class="section level3 hasAnchor" number="2.2.3">
<h3><span class="header-section-number">2.2.3</span> Statistical approaches<a href="hiv-aids.html#statistical-approaches" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>The challenges above make direct interpretation of the data often misleading or impossible.
Careful statistical modelling is required to overcome these limitations as best as possible.</p>
<ol style="list-style-type: decimal">
<li><p><strong>Borrowing information</strong>:
When little direct data are available, data judged to be indirectly related can be used to help improve estimation.
For example, if limited data are available for individuals of a certain age, it is likely reasonable to make use of data for individuals of a similar age.
As well as over age groups, information can be borrowed between and within countries, and across times.</p></li>
<li><p><strong>Evidence synthesis</strong>:
Multiple sources of evidence can be combined to overcome the limitations of any one data source.
For example, infrequently run household surveys can be complemented by more up-to-date programmatic data.</p></li>
<li><p><strong>Expert guidance</strong>:
Expert epidemiological, demographic, and local stakeholder guidance can be used to improve estimates.
Ensuring the quality of any data used in the estimation process is essential.</p></li>
<li><p><strong>Uncertainty quantification</strong>:
Conclusions drawn by synthesising multiple incomplete data sources are unlikely to be firm and unanimous.
It is therefore particularly that the uncertainties inherent to any statistical analysis are accurately and transparently presented.</p></li>
</ol>

</div>
</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body hanging-indent">
<div id="ref-auvert2005randomized" class="csl-entry">
Auvert, Bertran, Dirk Taljaard, Emmanuel Lagarde, Joelle Sobngwi-Tambekou, Rémi Sitta, and Adrian Puren. 2005. <span>“<span class="nocase">Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial</span>.”</span> <em>PLoS Medicine</em> 2 (11): e298.
</div>
<div id="ref-bailey2007male" class="csl-entry">
Bailey, Robert C, Stephen Moses, Corette B Parker, Kawango Agot, Ian Maclean, John N Krieger, Carolyn FM Williams, Richard T Campbell, and Jeckoniah O Ndinya-Achola. 2007. <span>“Male Circumcision for HIV Prevention in Young Men in Kisumu, Kenya: A Randomised Controlled Trial.”</span> <em>The Lancet</em> 369 (9562): 643–56.
</div>
<div id="ref-barre1983isolation" class="csl-entry">
Barré-Sinoussi, Françoise, Jean-Claude Chermann, Fran Rey, Marie Therese Nugeyre, Sophie Chamaret, Jacqueline Gruest, Charles Dauguet, et al. 1983. <span>“Isolation of a t-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS).”</span> <em>Science</em> 220 (4599): 868–71.
</div>
<div id="ref-broyles2023risk" class="csl-entry">
Broyles, Laura N, Robert Luo, Debi Boeras, and Lara Vojnov. 2023. <span>“The Risk of Sexual Transmission of HIV in Individuals with Low-Level HIV Viraemia: A Systematic Review.”</span> <em>The Lancet</em>.
</div>
<div id="ref-cohen2011prevention" class="csl-entry">
Cohen, Myron S, Ying Q Chen, Marybeth McCauley, Theresa Gamble, Mina C Hosseinipour, Nagalingeswaran Kumarasamy, James G Hakim, et al. 2011. <span>“Prevention of HIV-1 Infection with Early Antiretroviral Therapy.”</span> <em>New England Journal of Medicine</em> 365 (6): 493–505.
</div>
<div id="ref-eaton2022aids" class="csl-entry">
Eaton, W Jeffrey. 2022. <span>“<span class="nocase">Precision public health and infectious diseases</span>.”</span> In <em>AIDS2022: Strengthening Health Systems Session.</em>
</div>
<div id="ref-economist2023triple" class="csl-entry">
Economist Impact. 2023. <span>“A Triple Dividend: The Health, Social and Economic Gains from Financing the HIV Response in Africa.”</span>
</div>
<div id="ref-gottlieb1981pneumocystis" class="csl-entry">
Gottlieb, Michael S, Howard M Schanker, Peng Thim Fan, Andrew Saxon, Joel D Weisman, Irving Pozalski, et al. 1981. <span>“Pneumocystis Pneumonia—Los Angeles.”</span> <em>Mmwr</em> 30 (21): 1–3.
</div>
<div id="ref-grabowski2017hiv" class="csl-entry">
Grabowski, M Kate, David M Serwadda, Ronald H Gray, Gertrude Nakigozi, Godfrey Kigozi, Joseph Kagaayi, Robert Ssekubugu, et al. 2017. <span>“HIV Prevention Efforts and Incidence of HIV in Uganda.”</span> <em>New England Journal of Medicine</em> 377 (22): 2154–66.
</div>
<div id="ref-gray2007male" class="csl-entry">
Gray, Ronald H, Godfrey Kigozi, David Serwadda, Frederick Makumbi, Stephen Watya, Fred Nalugoda, Noah Kiwanuka, et al. 2007. <span>“<span class="nocase">Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial</span>.”</span> <em>The Lancet</em> 369 (9562): 657–66.
</div>
<div id="ref-gregson2006hiv" class="csl-entry">
Gregson, Simon, Geoffrey P Garnett, Constance A Nyamukapa, Timothy B Hallett, James JC Lewis, Peter R Mason, Stephen K Chandiwana, and Roy M Anderson. 2006. <span>“HIV Decline Associated with Behavior Change in Eastern Zimbabwe.”</span> <em>Science</em> 311 (5761): 664–66.
</div>
<div id="ref-khoury2016precision" class="csl-entry">
Khoury, Muin J, Michael F Iademarco, and William T Riley. 2016. <span>“Precision Public Health for the Era of Precision Medicine.”</span> <em>American Journal of Preventive Medicine</em> 50 (3): 398–401.
</div>
<div id="ref-monod2023growing" class="csl-entry">
Monod, Mélodie, Andrea Brizzi, Ronald M Galiwango, Robert Ssekubugu, Yu Chen, Xiaoyue Xi, Edward Nelson Kankaka, et al. 2023. <span>“Growing Gender Disparity in HIV Infection in Africa: Sources and Policy Implications.”</span> <em>medRxiv</em>, 2023–03.
</div>
<div id="ref-ord2013moral" class="csl-entry">
Ord, Toby. 2013. <span>“The Moral Imperative Toward Cost-Effectiveness in Global Health.”</span> <em>Center for Global Development</em> 12.
</div>
<div id="ref-pisani2003hiv" class="csl-entry">
Pisani, Elizabeth, Stefano Lazzari, Neff Walker, and Bernhard Schwartländer. 2003. <span>“HIV Surveillance: A Global Perspective.”</span> <em>JAIDS Journal of Acquired Immune Deficiency Syndromes</em> 32: S3–11.
</div>
<div id="ref-risher2021age" class="csl-entry">
Risher, Kathryn A, Anne Cori, Georges Reniers, Milly Marston, Clara Calvert, Amelia Crampin, Tawanda Dadirai, et al. 2021. <span>“Age Patterns of HIV Incidence in Eastern and Southern Africa: A Modelling Analysis of Observational Population-Based Cohort Studies.”</span> <em>The Lancet HIV</em> 8 (7): e429–39.
</div>
<div id="ref-siegfried2011antiretrovirals" class="csl-entry">
Siegfried, Nandi, Lize van der Merwe, Peter Brocklehurst, and Tin Tin Sint. 2011. <span>“Antiretrovirals for Reducing the Risk of Mother-to-Child Transmission of HIV Infection.”</span> <em>Cochrane Database of Systematic Reviews</em>, no. 7.
</div>
<div id="ref-stevens2022key" class="csl-entry">
Stevens, Oliver, Keith Sabin, Sonia Arias Garcia, Rebecca Anderson, Kalai Willis, Abu Abdul-Quader, Anne McIntyre, et al. 2022. <span>“Key Population Size, HIV Prevalence, and ART Coverage in Sub-Saharan Africa: Systematic Collation and Synthesis of Survey Data.”</span> <em>medRxiv</em>, 2022–07.
</div>
<div id="ref-stover2021impact" class="csl-entry">
Stover, John, and Yu Teng. 2021. <span>“The Impact of Condom Use on the HIV Epidemic.”</span> <em>Gates Open Research</em> 5.
</div>
<div id="ref-tanser2014concentrated" class="csl-entry">
Tanser, Frank, Tulio de Oliveira, Mathieu Maheu-Giroux, and Till Bärnighausen. 2014. <span>“Concentrated HIV Sub-Epidemics in Generalized Epidemic Settings.”</span> <em>Current Opinion in HIV and AIDS</em> 9 (2): 115.
</div>
<div id="ref-tatem2017worldpop" class="csl-entry">
Tatem, Andrew J. 2017. <span>“WorldPop, Open Data for Spatial Demography.”</span> <em>Scientific Data</em> 4 (1): 1–4.
</div>
<div id="ref-unaids2022global" class="csl-entry">
UNAIDS. 2022. <span>“In Danger: UNAIDS Global AIDS Update 2022.”</span> <a href="https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update" class="uri">https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update</a>.
</div>
<div id="ref-unaids2023aidsinfo" class="csl-entry">
———. 2023a. <span>“<span class="nocase">AIDSinfo: Global data on HIV epidemiology and response</span>.”</span> <a href="https://aidsinfo.unaids.org/" class="uri">https://aidsinfo.unaids.org/</a>.
</div>
<div id="ref-unaids2023global" class="csl-entry">
———. 2023b. <span>“The Path That Ends AIDS: UNAIDS Global AIDS Update 2023.”</span> <a href="https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023" class="uri">https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023</a>.
</div>
<div id="ref-pepfar2022" class="csl-entry">
U.S. Department of State. 2022. <span>“<span>Latest Global Program Results</span>.”</span> <a href="https://www.state.gov/wp-content/uploads/2022/11/PEPFAR-Latest-Global-Results_December-2022.pdf" class="uri">https://www.state.gov/wp-content/uploads/2022/11/PEPFAR-Latest-Global-Results_December-2022.pdf</a>.
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="introduction.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="bayes-st.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": false,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": false
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/ulyngs/oxforddown/tree/master/02-hiv-aids.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
